Scholar Rock Holding Corp (SRRK)

$44.23 -1.06 (-2.34%)
Market Cap 5.20B
Revenue (ttm) 0.00
Net Income (ttm) -246.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.41
Volume 1,055,300
Avg Vol 1,065,274
Day's Range N/A - N/A
Shares Out 114.88M
Stochastic %K 53%
Beta 0.70
Analysts Strong Sell
Price Target $55.07

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that loca...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 3860
Address:
301 Binney Street, 3rd Floor, Cambridge, United States
cheating_stock_investor
cheating_stock_investor Mar. 9 at 6:39 PM
$SRRK there is a reason an analyst gave this company a 70 pt.
0 · Reply
Tdorsey1776
Tdorsey1776 Mar. 9 at 4:34 PM
$SRRK Added 1500 down here. GLTA
1 · Reply
TwongStocks
TwongStocks Mar. 6 at 10:20 PM
$REGN $SRRK INCY SEC filing today. They confirmed they received a CRL on Feb 27 due to the Catalent Indiana facility. https://www.sec.gov/ix?doc=/Archives/edgar/data/0000879169/000087916926000013/incy-20260227.htm Appears that the Catalent Indiana still has issues.
1 · Reply
Tdorsey1776
Tdorsey1776 Mar. 4 at 7:21 PM
$SRRK Healthy blocks trading, big boy action today
0 · Reply
erevnon
erevnon Mar. 4 at 6:55 PM
Citigroup maintains Scholar Rock Holding $SRRK at Buy and raises the price target from $55 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 4 at 6:50 PM
$SRRK going over $50 real soon...4 upgrades today-high as $70 from BMO.
0 · Reply
Tdorsey1776
Tdorsey1776 Mar. 4 at 5:31 PM
$SRRK Still cheap here.
0 · Reply
erevnon
erevnon Mar. 4 at 3:27 PM
Barclays maintains Scholar Rock Holding $SRRK at Overweight and raises the price target from $52 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Mar. 4 at 1:18 PM
Piper Sandler⬆️the PT on $SRRK to $58 from $51, reiterated at Overweight and said, Regulatory Interactions Bode Well for Near-Term SMA Launch—We Remain Buyers $RHHBY $BIIB $LLY $NVO Here's what else Piper Sandler had to say: https://x.com/Quantumup1/status/2029184213132460307?s=20
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 10:27 PM
$SRRK Current Stock Price: $44.40 Contracts to trade: $45.0 SRRK Mar 20 2026 Call Entry: $2.15 Exit: $3.72 ROI: 73% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on SRRK
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript

Mar 3, 2026, 4:42 PM EST - 6 days ago

Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 3, 2026, 3:26 PM EST - 6 days ago

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 3, 2026, 7:00 AM EST - 6 days ago

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Scholar Rock to Present at Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 19 days ago

Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2026, 4:15 PM EST - 24 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Feb 10, 2026, 8:00 AM EST - 27 days ago

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 1:15 PM EST - 2 months ago

Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Scholar Rock Highlights 2026 Strategic Priorities

Jan 12, 2026, 7:00 AM EST - 2 months ago

Scholar Rock Highlights 2026 Strategic Priorities

Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating

Jan 5, 2026, 11:59 PM EST - 2 months ago

Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 2 months ago

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 3:33 PM EST - 3 months ago

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 2:01 PM EST - 4 months ago

Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 14, 2025, 7:00 AM EST - 4 months ago

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks

Nov 13, 2025, 3:05 PM EST - 4 months ago

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks

CARS CHH HIMS LCID MPT NOG SPHR

Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)

Nov 10, 2025, 11:28 AM EST - 4 months ago

Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Nov 4, 2025, 8:00 AM EST - 4 months ago

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Oct 23, 2025, 8:00 AM EDT - 4 months ago

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions

Sep 23, 2025, 5:02 PM EDT - 5 months ago

Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

Sep 23, 2025, 11:32 AM EDT - 5 months ago

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Sep 23, 2025, 8:16 AM EDT - 5 months ago

Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

FLY

US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:12 AM EDT - 5 months ago

US FDA declines to approve Scholar Rock's muscle weakness drug

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Sep 23, 2025, 7:00 AM EDT - 5 months ago

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Aug 14, 2025, 8:00 AM EDT - 7 months ago

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:33 PM EDT - 7 months ago

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Jul 21, 2025, 8:00 AM EDT - 8 months ago

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Jun 24, 2025, 6:25 PM EDT - 9 months ago

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Jun 23, 2025, 8:00 AM EDT - 9 months ago

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Jun 18, 2025, 10:47 AM EDT - 9 months ago

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

LLY

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Jun 18, 2025, 7:33 AM EDT - 9 months ago

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:12 AM EDT - 9 months ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Jun 18, 2025, 7:00 AM EDT - 9 months ago

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Jun 2, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock to Present at the Jefferies Global Healthcare Conference

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:30 PM EDT - 10 months ago

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 14, 2025, 7:00 AM EDT - 10 months ago

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

May 7, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Apr 28, 2025, 6:50 AM EDT - 11 months ago

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 25, 2025, 7:30 AM EDT - 1 year ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Mar 17, 2025, 12:21 PM EDT - 1 year ago

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 1:23 PM EST - 1 year ago

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 27, 2025, 7:00 AM EST - 1 year ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:15 PM EST - 1 year ago

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 21, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Jan 30, 2025, 8:37 AM EST - 1 year ago

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Jan 29, 2025, 8:05 AM EST - 1 year ago

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

cheating_stock_investor
cheating_stock_investor Mar. 9 at 6:39 PM
$SRRK there is a reason an analyst gave this company a 70 pt.
0 · Reply
Tdorsey1776
Tdorsey1776 Mar. 9 at 4:34 PM
$SRRK Added 1500 down here. GLTA
1 · Reply
TwongStocks
TwongStocks Mar. 6 at 10:20 PM
$REGN $SRRK INCY SEC filing today. They confirmed they received a CRL on Feb 27 due to the Catalent Indiana facility. https://www.sec.gov/ix?doc=/Archives/edgar/data/0000879169/000087916926000013/incy-20260227.htm Appears that the Catalent Indiana still has issues.
1 · Reply
Tdorsey1776
Tdorsey1776 Mar. 4 at 7:21 PM
$SRRK Healthy blocks trading, big boy action today
0 · Reply
erevnon
erevnon Mar. 4 at 6:55 PM
Citigroup maintains Scholar Rock Holding $SRRK at Buy and raises the price target from $55 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 4 at 6:50 PM
$SRRK going over $50 real soon...4 upgrades today-high as $70 from BMO.
0 · Reply
Tdorsey1776
Tdorsey1776 Mar. 4 at 5:31 PM
$SRRK Still cheap here.
0 · Reply
erevnon
erevnon Mar. 4 at 3:27 PM
Barclays maintains Scholar Rock Holding $SRRK at Overweight and raises the price target from $52 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Mar. 4 at 1:18 PM
Piper Sandler⬆️the PT on $SRRK to $58 from $51, reiterated at Overweight and said, Regulatory Interactions Bode Well for Near-Term SMA Launch—We Remain Buyers $RHHBY $BIIB $LLY $NVO Here's what else Piper Sandler had to say: https://x.com/Quantumup1/status/2029184213132460307?s=20
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 10:27 PM
$SRRK Current Stock Price: $44.40 Contracts to trade: $45.0 SRRK Mar 20 2026 Call Entry: $2.15 Exit: $3.72 ROI: 73% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 3 at 7:18 PM
$SRRK If you listened to the call this morning it is DERISKED- most favorably they have resolved the issues at NOVO's Catalent facility and they will submit their BLA most likely in April.
0 · Reply
Quantumup
Quantumup Mar. 3 at 7:06 PM
BMO Capital⬆️ $SRRK's PT to $70 from $50 and reiterated at Outperform, and said, Progress marches on as site re-inspection and potential approval nears. $RHHBY $BIIB $LLY $NVO BMO Capital added—Tone from management reflects confidence that apitegromab's Catalent site re-inspection and review could be faster than some expected under a type Il resubmission. On improved confidence in approval and now slightly higher pricing considerations for apitegromab, we move our target price to $70. While apitegromab's initial launch may be somewhat slowed by initial efforts to secure access, we do not see this as a long-term barrier to sales. Ph 1 SRK-439 healthy volunteers data could start to show pipeline diversity.
0 · Reply
d_risk
d_risk Mar. 3 at 5:18 PM
$SRRK - Scholar Rock Holding Corporation - 10K - Updated Risk Factors SRRK’s risk profile worsened with an FDA CRL tied to a non‑compliant fill‑finish CMO that’s delaying apitegromab’s BLA, potentially jeopardizing EMA review, EU pricing/reimbursement and rare pediatric voucher hopes, while exposing supply‑chain fragility and adding macro, tariff, regulatory and patient-support compliance risks. #Biotechnology #RegulatoryRisk #SupplyChain #RareDiseases #FDAApproval 🟢 Added 🟠 Removed https://d-risk.ai/SRRK/10-K/2026-03-03
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 3 at 1:40 PM
$SRRK (+6.3% pre) Scholar Rock Holding: Q4 Earnings Insights https://ooc.bz/l/95260
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 3 at 1:27 PM
$SRRK up we go...
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 3 at 1:17 PM
$SRRK Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.88 down -44.26% YoY • Scholar Rock expects existing cash, cash equivalents, and marketable securities to fund operations and capital expenditures into 2027, with commercial product launches for apitegromab anticipated in 2026 if approved.
0 · Reply
mikesterz7
mikesterz7 Mar. 3 at 12:50 PM
$SRRK SCHOLAR ROCK HOLDNG CRP posted quarterly earnings results for Q4 2025 on Tuesday, March 3rd. The company reported earnings of -$0.88 per share, beating estimates of -$0.91 by $0.03.
0 · Reply
CapitalVector
CapitalVector Feb. 20 at 1:46 PM
$SRRK Scholar Rock develops therapies for neuromuscular diseases. Clinical execution drives valuation. Development risk remains elevated.
0 · Reply
kareem1988
kareem1988 Feb. 18 at 11:05 AM
Which of these biotechs with strong funding and massive 2026 catalysts has the brightest future? $DRTS (Alpha Tau Medical) – Their Alpha DaRT technology is a literal game-changer for solid tumors. Strong clinical momentum and a unique niche in radiotherapy. $VKTX (Viking Therapeutics) – A powerhouse in the obesity/MASH space. With billions in cash and highly competitive GLP-1 data, they are a prime acquisition target. $SRRK (Scholar Rock) – Recent Phase 3 wins in SMA and a robust balance sheet. They are transitioning from clinical stage to a commercial contender. $CRSP (CRISPR Therapeutics) – The leader in gene editing with "Casgevy" already hitting the market and a massive war chest to fund their next-gen oncology pipeline.
2 · Reply
PriceRover
PriceRover Feb. 18 at 10:10 AM
$SRRK Biotech with RNA-based platform; pipeline depth matters.
0 · Reply
MAGA1717
MAGA1717 Feb. 17 at 11:27 PM
$SRRK this thing is the real deal. will be a $500 + stock one day. dont forget the +
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 6:40 PM
$SRRK RSI: 56.12, MACD: 0.8582 Vol: 1.53, MA20: 45.93, MA50: 45.03 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply